Negar Etehad Roodi1, Nushin Karkuki Osguei2, Mahdy Hasanzadeh Daloee3, Alireza Pasdar4, Majid Ghayour-Mobarhan5, Gordon Ferns6, Ali Samadi Kuchaksaraei1. 1. Cellular and Molecular Research Centre, Iran University of Medical Science, Tehran, Iran. 2. Eposcience Millennium Institute, Tehran, Iran. 3. Cardiovascular Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Molecular Medicine Group, Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is a leading cause of death, supporting the need for the identification of novel biomarkers as risk stratification factors. Endonuclease G (ENDOG) has recently been suggested to be a novel determinant of cardiac hypertrophy and mitochondrial function, and plays an important role in apoptosis processes involved in cardiac myocyte death. The aim of current study was to explore the association of two genetic variants in ENDOG gene (ENDOG) with CVD risk factors in an Iranian population. METHODS: Subjects included 663 patients with CVD and 282 healthy individuals recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders Cohort Study. The ENDOG S12L (rs 2293969) and L142M (rs 61397314) variants were genotyped. Anthropometric and biochemical factors were measured in all the subjects followed by univariate and multivariate analyses to determine the association of these genetic markers with CVD and biochemical parameters. RESULTS: ENDOG polymorphisms were found at a significantly higher prevalence in individuals who had histories of smoking and breaking point in L142M. In contrast, other risk factors for cardiovascular disease, including lipid profile and blood pressure, showed no or very weak relationship with the ENDOG polymorphisms. CONCLUSION: Our findings indicated an association between an ENDOG genetic variant and smoking history as a cardiovascular risk factor. Further studies in the prospective setting are warranted to investigate the value of this marker.
BACKGROUND: Cardiovascular disease (CVD) is a leading cause of death, supporting the need for the identification of novel biomarkers as risk stratification factors. Endonuclease G (ENDOG) has recently been suggested to be a novel determinant of cardiac hypertrophy and mitochondrial function, and plays an important role in apoptosis processes involved in cardiac myocyte death. The aim of current study was to explore the association of two genetic variants in ENDOG gene (ENDOG) with CVD risk factors in an Iranian population. METHODS: Subjects included 663 patients with CVD and 282 healthy individuals recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders Cohort Study. The ENDOG S12L (rs 2293969) and L142M (rs 61397314) variants were genotyped. Anthropometric and biochemical factors were measured in all the subjects followed by univariate and multivariate analyses to determine the association of these genetic markers with CVD and biochemical parameters. RESULTS: ENDOG polymorphisms were found at a significantly higher prevalence in individuals who had histories of smoking and breaking point in L142M. In contrast, other risk factors for cardiovascular disease, including lipid profile and blood pressure, showed no or very weak relationship with the ENDOG polymorphisms. CONCLUSION: Our findings indicated an association between an ENDOG genetic variant and smoking history as a cardiovascular risk factor. Further studies in the prospective setting are warranted to investigate the value of this marker.
Authors: Marisol Ruiz-Meana; Javier Inserte; Celia Fernandez-Sanz; Victor Hernando; Elisabet Miro-Casas; Ignasi Barba; David Garcia-Dorado Journal: Basic Res Cardiol Date: 2011-09-30 Impact factor: 17.165
Authors: Yeong-Hoon Choi; Douglas B Cowan; Adrian M Moran; Steven D Colan; Christof Stamm; Koh Takeuchi; Ingeborg Friehs; Pedro J del Nido; Francis X McGowan Journal: J Thorac Cardiovasc Surg Date: 2009-03-17 Impact factor: 5.209
Authors: Chris McDermott-Roe; Junmei Ye; Rizwan Ahmed; Xi-Ming Sun; Anna Serafín; James Ware; Leonardo Bottolo; Phil Muckett; Xavier Cañas; Jisheng Zhang; Glenn C Rowe; Rachel Buchan; Han Lu; Adam Braithwaite; Massimiliano Mancini; David Hauton; Ramon Martí; Elena García-Arumí; Norbert Hubner; Howard Jacob; Tadao Serikawa; Vaclav Zidek; Frantisek Papousek; Frantisek Kolar; Maria Cardona; Marisol Ruiz-Meana; David García-Dorado; Joan X Comella; Leanne E Felkin; Paul J R Barton; Zoltan Arany; Michal Pravenec; Enrico Petretto; Daniel Sanchis; Stuart A Cook Journal: Nature Date: 2011-10-05 Impact factor: 49.962
Authors: M Chiong; Z V Wang; Z Pedrozo; D J Cao; R Troncoso; M Ibacache; A Criollo; A Nemchenko; J A Hill; S Lavandero Journal: Cell Death Dis Date: 2011-12-22 Impact factor: 8.469
Authors: Kenneth V Nyombi; Samuel Kizito; David Mukunya; Angella Nabukalu; Martin Bukama; Joseph Lunyera; Martha Asiimwe; Ivan Kimuli; Robert Kalyesubula Journal: BMC Res Notes Date: 2016-02-17